News

The randomized, double-blind, placebo controlled, dose-escalation study achieved statistical significance in its primary endpoint of mean change in FEV1 (forced expiratory volume in 1 second) from baseline at

A poster, titled ‘Neuroprotection in CNS demyelinating disease by SIRT1 activators, a potential oral therapy’ presented at the annual meeting of the american neurological association, showed that oral

AstraZeneca has agreed to pay $30 million to acquire NPS’s assets. NPS intends to use the proceeds to support further development of its late-stage product pipeline. Under the

Mixed dyslipidemia is the presence of elevated levels of bad cholesterol, low-density lipoproteins and triglycerides, and low levels of good cholesterol, high-density lipoproteins in the blood. The Phase

The dose-sparing ability could be critical in extending limited vaccine supplies to protect a great number of people in the event of a pandemic influenza outbreak, according to

Through X-ray crystallographic studies, Ariad says its study shows in detail how inhibitors of the Bcr-Abl protein, such as AP24534, are able to overcome the structural changes induced

Amarin believes that its lipid-based technology platform for the targeted transport of molecules through the liver or to the brain can be leveraged in a wide range of

In the safety study, Advaxis reported treatment of 15 patients in three dosage groups with 30 minute 250ml infusions of Lovaxin C at 3-week intervals. Patients were observed

The compound, civamide, a proprietary TRPV-1 receptor modulator and neuronal calcium channel blocker, is in Phase III clinical trials in an intranasal formulation to treat various types of